Asthma and COPD Therapies Market Forecast 2014-2024 : Opportunities for Leading Companies

世界の喘息及びCOPD(慢性閉塞性肺疾患)治療薬市場

◆タイトル:Asthma and COPD Therapies Market Forecast 2014-2024 : Opportunities for Leading Companies
◆商品コード:VGAIN4120203
◆調査・発行会社:visiongain
◆発行日:2014年10月
◆ページ数:335
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single user licence(1名使用、1年)GBP1,799 ⇒換算¥269,850見積依頼/購入/質問フォーム
Dept Licence(5名まで共有可、1年)GBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site Licence(全社内共有可、PDF制限なし)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、世界の喘息及びCOPD(慢性閉塞性肺疾患)治療薬市場について調査・分析し、イントロダクション、セグメント別市場分析、地域別市場分析、市場環境分析、専門家の見解、主要企業分析データなどをお届けいたします。

Asthma and COPD therapies – new study showing you trends, R&D progress, and predicted revenues
Where’s the asthma and COPD therapies market heading? Visiongain’s brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 335-page report provides 264 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharma market.

Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter’s Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of six exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
• Clive Page, Professor of Pharmacology, King’s College London
• Monica Fletcher, Chief Executive, Education for Health
• Daphne Tsitoura, Senior Medical Director, GSK
• Barbara Yawn, Director of Research, Olmsted Medical Center
• Ahmed Wagih, Product Manager, Respiratory Franchise, GSK

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you see forecasts to 2024 for the following submarkets:
• Bronchodilator monotherapy – SABAs, LABAs, anticholinergic drugs
• Anti-inflammatory drugs – inhaled corticosteroids, anti-leukotrienes, monoclonal antibodies
• Combination drugs.
Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for products
How will leading drugs and promising products currently in development perform to 2024 at world level? Our study forecasts sales of 27 products, including these:
• Advair/Seretide
• Atrovent
• Combivent
• Flixotide/Flovent
• Pulmicort
• Singulair
• Spiriva
• Symbicort
• Ventolin
• Xolair
• Reslizumab
• Mepolizumab
Discover how high revenues can go. You see what’s happening, understanding trends, challenges and opportunities.
Our analysis also breaks the main world forecast into geographical markets.

What are the prospects in the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 12 national markets to 2024:
• US
• Japan
• China
• Germany
• France
• UK
• Italy
• Spain
• India
• Brazil
• Russia
• Mexico
• Rest of the World

There will be growth in established pharma markets and in developing countries. Our analyses show that India, Russia, China and Mexico, in particular, will continue to achieve high revenue growth to 2024. Developments worldwide in product approval and pricing will influence the market.

Leading companies and potential for market growth
Overall world revenue for asthma and COPD therapies will reach $33.1bn in 2014, our work forecasts. We predict slow revenue growth from 2014 to 2018 and faster growth from 2018 to 2024. Rising demand for asthma and COPD drugs, expanding healthcare coverage, new drugs for severe asthma and a strong R&D pipeline will increase sales to 2024.

Our work shows you what organisations hold greatest potential. See profiles of 7 leading companies, including these:
• AstraZeneca
• Boehringer Ingelheim
• GSK
• Merck
• Novartis
• Roche
• Teva.

【レポートの目次】

1. Report Overview
1.1 Global Asthma and COPD Therapies Market Overview
1.2 Global Asthma and COPD Therapies Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Asthma and COPD Therapies
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 Overview of Respiratory Diseases
2.2.1 Classifying Respiratory Diseases: Obstructive and Restrictive
2.3 What is Asthma?
2.3.1 Trends in Asthma Prevalence
2.3.2 Pathophysiology of Asthma
2.3.3 Symptoms of Asthma
2.3.4 Causes and Triggers for Asthma
2.3.5 Treatment of Asthma
2.3.6 Guidelines for Asthma Treatment
2.3.7 Drug Treatments for Asthma
2.3.8 Drug Delivery Methods in Asthma
2.4 What is Chronic Obstructive Pulmonary Disease (COPD)?
2.4.1 Trends in COPD Prevalence
2.4.2 Pathophysiology of COPD
2.4.3 Signs and Symptoms of COPD
2.4.4 Treatment of COPD
2.4.5 Drug Treatments for COPD
2.4.6 Guidelines for COPD Treatment
2.5 Major Drug Classes in the Treatment of Asthma and COPD
2.5.1 Bronchodilators
2.5.1.1 Beta2-Agonists
2.5.1.2 Anticholinergics
2.5.2 Anti-Inflammatory Drugs
2.5.2.1 Corticosteroids
2.5.2.2 Leukotriene Receptor Antagonists
2.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease
2.5.3 Combination Drugs
2.5.4 Drugs for Allergic Rhinitis
2.6 Phases of Clinical Trials
2.7 Scope of this Report
2.8 Currency Exchange Rates in This Report
3. Asthma and COPD Therapies: World Market 2014-2024
3.1 The World Respiratory Drugs Market by Therapeutic Area
3.2 The World Asthma and COPD Therapies Market in 2013
3.2.1 Leading Asthma and COPD Therapies
3.2.2 Leading Companies in the Asthma and COPD Therapies Market
3.3 World Asthma and COPD Therapies Market: Sales Forecast by Therapeutic Area, 2014-2024
3.3.1 World Asthma Therapies Market: Sales Forecast 2014-2024
3.3.2 World COPD Therapies Market: Sales Forecast 2014-2024
3.4 World Asthma and COPD Therapies Market: Sales Forecast by Drug Class 2014-2024
3.5 Combination Drugs Lead the Asthma and COPD Therapies Market
3.6 How Will Segmental Market Shares Change to 2024?
3.6.1 World Asthma and COPD Therapies Market: Drivers and Restraints 2014-2024
3.7 Asthma and COPD Therapies: Trends and Developments
3.7.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers
3.7.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?
4. Leading National Markets 2014-2024
4.1 Regional Breakdown of the World Asthma and COPD Therapies Market
4.2 World Asthma and COPD Therapies Market: Regional Forecast 2014-2024
4.2.1 How Will Regional Market Shares Change to 2024?
4.3 National Breakdown of the World Asthma and COPD Therapies Market
4.4 World Asthma and COPD Therapies Market: National Markets Forecast 2014-2024
4.4.1 How Will National Market Shares Change to 2024?
4.5 The US Asthma and COPD Therapies Market 2014-2024
4.5.1 US Asthma and COPD Therapies Market Forecast 2014-2024
4.5.2 US Asthma and COPD Therapies Market: Trends and Developments
4.5.2.1 Increasing COPD Prevalence in the US
4.5.2.2 FDA Issues Draft Guidance on Generic Inhaler Bioequivalence
4.5.2.3 Pharmacy Benefit Managers Alter Formulary Status of Advair
4.6 Japanese Asthma and COPD Therapies Market 2014-2024
4.6.1 Japanese Asthma and COPD Therapies Market Forecast 2014-2024
4.6.2 Japanese Asthma and COPD Therapies Market: Trends and Developments
4.6.2.1 Generic Penetration to Reach 60% by 2018?
4.6.2.2 Japanese Pharmaceutical Industry Regulatory Reform
4.7 EU5 Asthma and COPD Therapies Market 2014-2024
4.7.1 German Asthma and COPD Therapies Market Forecast 2014-2024
4.7.2 French Asthma and COPD Therapies Market Forecast 2014-2024
4.7.3 UK Asthma and COPD Therapies Market Forecast 2014-2024
4.7.4 Italian Asthma and COPD Therapies Market Forecast 2014-2024
4.7.5 Spanish Asthma and COPD Therapies Market Forecast 2014-2024
4.7.6 EU5 Asthma and COPD Therapies Market: Trends and Developments
4.7.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law
4.7.6.2 France: Social Security Finance Bill 2014
4.7.6.3 UK: Improving Asthma and COPD Patient Outcomes
4.7.6.4 Italy: Austerity Measures Limiting Growth
4.7.6.5 Spain: The Start of Recovery in the Spanish Economy
4.8 BRIC Asthma and COPD Therapies Market 2014-2024
4.8.1 Chinese Asthma and COPD Therapies Market Forecast 2014-2024
4.8.2 Chinese Asthma and COPD Therapies Market: Trends and Developments
4.8.2.1 China’s Industrial Future and Asthma/COPD
4.8.2.2 Expansion of Healthcare Coverage and Reimbursement
4.8.2.3 Price Controls and the Anhui Model
4.8.3 Brazilian Asthma and COPD Therapies Market Forecast 2014-2024
4.8.4 Brazilian Asthma and COPD Therapies Market: Trends and Developments
4.8.4.1 Increasing Access to Medicines
4.8.5 Indian Asthma and COPD Therapies Market Forecast 2014-2024
4.8.6 Indian Asthma and COPD Therapies Market: Trends and Developments
4.8.6.1 Drug Prices Control Order 2013
4.8.6.2 Expansion of Healthcare Provision
4.8.7 Russian Asthma and COPD Therapies Market Forecast 2014-2024
4.8.8 Russian Asthma and COPD Therapies Market: Trends and Developments
4.8.8.1 No Embargo on Foreign Drug Imports
4.8.8.2 Pharma2020 and the Russian Pharmaceutical Industry
4.9 Mexican Asthma and COPD Therapies Market 2014-2024
4.9.1 Mexican Asthma and COPD Therapies Market Forecast 2014-2024
4.9.2 Mexican Asthma and COPD Therapies Market: Trends and Developments
4.9.2.1 Seguro Popular: Mexican Healthcare Reform
4.9.2.2 COFEPRIS: Regulatory Changes and Improvements
4.9.2.3 Mexico’s Agreement for Innovation
5. Bronchodilator Monotherapy Market 2014-2024
5.1 Introduction to Bronchodilator Monotherapy
5.2 The Bronchodilator Monotherapy Market in 2013
5.2.1 Leading Bronchodilators in 2013
5.3 Bronchodilator Monotherapy: Market Forecast 2014-2024
5.4 How Will Market Shares by Drug Class Change to 2024?
5.5 The Short-Acting Beta2-Agonist (SABA) Market 2014-2024
5.5.1 Leading SABAs in 2013
5.5.2 SABAs: Market Forecast 2014-2024
5.5.3 Market Share of Leading SABAs to 2024
5.5.4 Ventolin (salbutamol, GSK)
5.5.4.1 Ventolin: Sales Forecast 2014-2024
5.5.5 ProAir (salbutamol, Teva)
5.5.5.1 ProAir: Sales Forecast 2014-2024
5.5.6 Proventil (salbutamol, Merck)
5.5.6.1 Proventil: Sales Forecast 2014-2024
5.5.7 Xopenex (levosalbutamol, Dainippon Sumitomo)
5.5.7.1 Xopenex: Sales Forecast 2014-2024
5.6 The Long-Acting Beta2-Agonist (LABA) Market 2014-2024
5.6.1 Leading LABAs in 2013
5.6.2 LABAs: Market Forecast 2014-2024
5.6.3 Market Share of Leading LABAs to 2024
5.6.4 Foradil (formoterol, Merck/Novartis)
5.6.4.1 Foradil: Sales Forecast 2014-2024
5.6.5 Serevent (salmeterol, GSK)
5.6.5.1 Serevent: Sales Forecast 2014-2024
5.6.6 Arcapta/Onbrez (indacaterol, Novartis)
5.6.6.1 Arcapta/Onbrez: Sales Forecast 2014-2024
5.6.7 Brovana (arfomoterol, Dainippon Sumitomo)
5.6.7.1 Brovana: Sales Forecast 2014-2024
5.6.8 Striverdi (olodaterol, Boehringer Ingelheim)
5.6.8.1 Striverdi: Sales Forecast 2014-2024
5.7 The Anticholinergics Market 2014-2024
5.7.1 Leading Anticholinergics in 2013
5.7.2 Anticholinergics: Market Forecast 2014-2024
5.7.3 Market Share of Leading Anticholinergics to 2024
5.7.4 Spiriva (tiotropium, Boehringer Ingelheim)
5.7.4.1 Spiriva: Sales Forecast 2014-2024
5.7.5 Spiriva: Recent Developments
5.7.5.1 Safety Concerns and the UPLIFT Trial
5.7.5.2 Results of the POET Study
5.7.5.3 Competition from Combination Products
5.7.6 Atrovent (ipratropium, Boehringer Ingelheim)
5.7.6.1 Atrovent: Sales Forecast 2014-2024
5.7.7 Eklira/Tudorza/Bretaris (aclidinium, AstraZeneca/Forest/Menarini)
5.7.7.1 Eklira/Tudorza/Bretaris: Sales Forecast 2014-2024
6. Anti-Inflammatory Drugs Market 2014-2024
6.1 Introduction to Anti-Inflammatory Drugs
6.2 The Anti-Inflammatory Drugs Market in 2013
6.2.1 Leading Anti-Inflammatory Drugs in 2013
6.3 Anti-Inflammatory Drugs: Market Forecast 2014-2024
6.4 How Will Market Shares by Drug Class Change to 2024?
6.5 The Corticosteroids Market 2014-2024
6.5.1 Leading Corticosteroids in 2013
6.5.2 Corticosteroids: Market Forecast 2014-2024
6.5.3 Market Share of Leading Corticosteroids to 2024
6.5.4 Flixotide/Flovent (fluticasone propionate, GSK)
6.5.4.1 Flixotide/Flovent: Sales Forecast 2014-2024
6.5.5 Pulmicort (budesonide, AstraZeneca)
6.5.5.1 Pulmicort: Sales Forecast 2014-2024
6.5.6 QVAR (beclometasone, Teva)
6.5.6.1 QVAR: Sales Forecast 2014-2024
6.5.7 Asmanex (mometasone, Merck)
6.5.7.1 Asmanex: Sales Forecast 2014-2024
6.6 The Anti-Leukotrienes Market 2014-2024
6.6.1 Leading Anti-Leukotrienes in 2013
6.6.2 Anti-Leukotrienes: Market Forecast 2014-2024
6.6.2.1 Market Share of Leading Anti-Leukotrienes to 2024
6.6.3 Singulair (montelukast, Merck)
6.6.3.1 Singulair: Sales Forecast 2014-2024
6.7 The Monoclonal Antibodies Market 2014-2024
6.7.1 Monoclonal Antibodies: Market Forecast 2014-2024
6.7.1.1 Market Share of Leading Monoclonal Antibodies to 2024
6.7.2 Xolair (omalizumab, Novartis/Roche)
6.7.2.1 Xolair: Sales Forecast 2014-2024
6.7.3 Cinquil (reslizumab, Teva)
6.7.3.1 Cinquil: Sales Forecast 2014-2024
6.7.4 Mepolizumab (Bosatria, GSK)
6.7.4.1 Mepolizumab: Sales Forecast 2014-2024
6.7.5 Benralizumab (MEDI-563, AstraZeneca/Kyowa Hakko Kirin)
6.7.5.1 Benralizumab: Sales Forecast 2014-2024
6.7.6 Lebrikizumab (RG3637, Roche)
6.7.6.1 Lebrikizumab: Sales Forecast 2014-2024
6.7.7 Dupilumab (REGN668, Regeneron/Sanofi)
6.7.7.1 Dupilumab: Sales Forecast 2014-2024
7. Combination Drugs Market 2014-2024
7.1 Introduction to Combination Drugs
7.1.1 Leading Combination Drugs in 2013
7.2 Combination Drugs: Market Forecast 2014-2024
7.3 How Will Market Shares by Drug Change to 2024?
7.3.1 Advair/Seretide (fluticasone/salmeterol, GSK)
7.3.1.1 Advair/Seretide: Sales Forecast 2014-2024
7.3.2 Symbicort (budesonide/formoterol, AstraZeneca)
7.3.2.1 Symbicort: Sales Forecast 2014-2024
7.3.2.2 Symbicort: The SMART Concept
7.3.3 Combivent (ipratropium/salbutamol, Boehringer Ingelheim)
7.3.3.1 Combivent: Sales Forecast 2014-2024
7.3.4 Dulera (formoterol/mometasone, Merck)
7.3.4.1 Dulera: Sales Forecast 2014-2024
7.4 Recently Launched Combination Drugs
8. Leading Companies in the Asthma and COPD Therapies Market
8.1 Asthma and COPD Therapies: Increasing Competition
8.1.1 Leading Companies in Asthma and COPD in 2013
8.1.2 Leading Companies: Market Forecast 2014-2024
8.1.3 How Will Leading Companies’ Market Shares Change to 2024?
8.2 AstraZeneca
8.2.1 AstraZeneca: Asthma and COPD Therapies
8.2.2 AstraZeneca: Sales Forecast 2014-2024
8.2.3 AstraZeneca: Products in Development
8.2.4 AstraZeneca: Recent Developments
8.2.4.1 AstraZeneca Acquires Almirall’s Respiratory Portfolio
8.2.4.2 Acquisition of Pearl Therapeutics Expanded AstraZeneca’s Combination Drug Pipeline
8.2.4.3 AstraZeneca Rejects Pfizer Takeover Bid
8.3 Boehringer Ingelheim
8.3.1 Boehringer Ingelheim: Asthma and COPD Therapies
8.3.2 Boehringer Ingelheim: Sales Forecast 2014-2024
8.3.3 Boehringer Ingelheim: Products in Development
8.3.4 Boehringer Ingelheim: Recent Developments
8.3.4.1 Expansion of Respimat Manufacturing Capacity
8.3.4.2 Respimat Safety Concerns and the TIOSPIR Study
8.3.4.3 Ben Venue Laboratories Shut Down
8.4 GSK
8.4.1 GSK: Asthma and COPD Therapies
8.4.2 GSK: Sales Forecast 2014-2024
8.4.3 GSK: Products in Development
8.4.4 GSK: Recent Developments
8.4.4.1 Breo/Relvar and Anoro: Recently Launched Combination Drugs
8.4.4.2 Arnuity Ellipta Approved in the US
8.4.4.3 GSK Divests OTC Products
8.4.4.4 GSK Asset Swap with Novartis to Restructure Consumer Health
8.4.4.5 GSK Presents Data on Eosinophil Levels and COPD
8.5 Merck & Co. (Merck)
8.5.1 Merck: Asthma and COPD Therapies
8.5.2 Merck: Sales Forecast 2014-2024
8.5.3 Merck: Products in Development
8.5.4 Merck: Recent Developments
8.5.4.1 Bayer Acquires Merck’s Consumer Health Business
8.5.4.2 FDA Rejects Singulair OTC Switch
8.5.4.3 Takeda Ended Co-Promotion of Daxas with Merck
8.6 Novartis
8.6.1 Novartis: Asthma and COPD Therapies
8.6.2 Novartis: Sales Forecast 2014-2024
8.6.3 Novartis: Products in Development
8.6.4 Novartis: Recent Developments
8.6.4.1 Novartis Restructures Following Strategic Review
8.6.4.2 Novartis Presents Data on Ultibro and Seebri
8.6.4.3 Pfizer Promotes Two Novartis COPD drugs in the UK
8.7 Roche
8.7.1 Roche: Asthma and COPD Therapies
8.7.2 Roche: Sales Forecast 2014-2024
8.7.3 Roche: Products in Development
8.8 Teva
8.8.1 Teva: Asthma and COPD Therapies
8.8.2 Teva: Sales Forecast 2014-2024
8.8.3 Teva: Products in Development
8.8.4 Teva: Recent Developments
8.8.4.1 Launch of DuoResp Spiromax

9. Asthma and COPD Therapies Pipeline Analysis 2014-2024
9.1 A Strong Asthma and COPD Pipeline
9.2 The Bronchodilators Pipeline
9.2.1 Bronchodilators: Phase 3 Pipeline
9.2.1.1 PX1439 and PX1442 (Prosonix)
9.2.1.2 PT001 (glycopyrronium, AstraZeneca)
9.2.1.3 Spiriva Respimat (tiotropium, Boehringer Ingelheim)
9.2.1.4 GW642444 (vilanterol, GSK)
9.2.1.5 KRP-AB1102 (aclidinium, Kyorin Pharmaceutical)
9.2.1.6 Seebri Breezhaler (glycopyrronium, Novartis/Vectura)
9.2.1.7 QVAR BAI (beclometasone, Teva)
9.2.1.8 Albuterol MDPI/Albuterol Spiromax (salbutamol, Teva)
9.2.2 Bronchodilators: Phase 2 Pipeline
9.2.3 Bronchodilators: Phase 1 and Preclinical Pipeline
9.3 The Anti-Inflammatory Drugs Pipeline
9.3.1 Anti-Inflammatory Drugs: Phase 3 Pipeline
9.3.1.1 PSX1001 and PSX1050 (fluticasone propionate pMDI, Prosonix)
9.3.1.2 Masitinib (tyrosine kinase inhibitor, AB Science)
9.3.1.3 Inhaled Alpha-1 Antitrypsin (Kamada/Chiesi Farmaceutici)
9.3.1.4 VR506 (fluticasone propionate DPI, Vectura)
9.3.1.5 Favolir (budesonide, Vectura)
9.3.2 Anti-Inflammatory Drugs: Phase 2 Pipeline
9.3.3 Anti-Inflammatory Drugs: Phase 1 Pipeline
9.3.4 Anti-Inflammatory Drugs: Preclinical Pipeline
9.4 The Combination Drugs Pipeline
9.4.1 Combination Drugs: Phase 3 Pipeline
9.4.1.1 PSX2005 (fluticasone/salmeterol, Prosonix)
9.4.1.2 LAS40464 (aclidinium/formoterol, AstraZeneca)
9.4.1.3 PT003 (glycopyrronium/formoterol, AstraZeneca)
9.4.1.4 Tiotropium/Olodaterol Fixed-Dose Combination (LAMA/LABA, Boehringer Ingelheim)
9.4.1.5 Easyhaler Combination Drugs (Orion)
9.4.1.6 VR632 (ICS/LABA, Vectura/Sandoz)
9.4.2 Combination Drugs: Phase 2 Pipeline
9.4.3 Combination Drugs: Phase 1 and Preclinical Pipeline
9.5 Other Asthma and COPD Drugs Pipeline
10. Qualitative Analysis of the Asthma and COPD Therapies Market 2014-2024
10.1 SWOT Analysis of the Asthma and COPD Therapies Market
10.2 Strengths
10.2.1 Increasing Prevalence and Disease Burden
10.2.2 High Costs of Treatment
10.2.3 The Changing Perception of COPD
10.2.4 Patient Education: Understanding the Severity of Respiratory Disease
10.2.5 Lifecycle Management Strategies to Counter Patent Expiry
10.2.6 Advanced Inhaler Technologies to Counter Generic Erosion
10.2.7 Developments in Diagnostics
10.2.7.1 Diagnostic Imaging: Parametric Response Mapping for COPD
10.2.7.2 Biological Markers in COPD
10.3 Weaknesses
10.3.1 Under-Diagnosis: the ‘Ghost Population’
10.3.2 Side-Effects of Drug Classes
10.3.3 Patent Cliff for Devices
10.3.4 Low Patient Adherence
10.4 Opportunities
10.4.1 Patient Phenotyping and Personalised Medicine
10.4.2 A Strong R&D Pipeline
10.4.2.1 Ultra-Long-Acting Beta2-Agonists
10.4.2.2 Muscarinic Antagonists and Beta2-Agonists (MABAs)
10.4.2.3 Monoclonal Antibodies
10.4.2.4 LAMA/LABA Combinations
10.4.3 Growth in Emerging Markets
10.4.4 Opportunities in Telehealth
10.5 Threats
10.5.1 Patent Expiry and Generic Competition
10.5.2 Pharmacy Benefit Managers and Cost Control
10.5.3 The WISDOM Trial Could Reduce Steroid Use in COPD
10.6 Porter’s Five Forces Analysis of the Asthma and COPD Therapies Market
10.6.1 Rivalry Among Competitors [Medium]
10.6.2 Threat of New Entrants [Medium]
10.6.3 Power of Suppliers [Medium]
10.6.4 Power of Buyers [High]
10.6.5 Threat of Substitutes [Low]
11. Research Interviews
11.1 Interview with Professor Clive Page, Professor of Pharmacology and Director of the Sackler Institute of Pulmonary Pharmacology, King’s College London
11.1.1 Treating Different Phenotypes of Asthma and COPD
11.1.2 Personalised Medicine and Improved Existing Drug Classes
11.1.3 Phenotyping of Asthma/COPD, Diagnosis and Treatment
11.1.4 WISDOM Trial: Questioning the Role of Steroids in COPD
11.1.5 Monoclonal Antibodies in Severe Asthma
11.1.6 Healthcare Costs and the Importance of Prevention
11.1.7 Areas to Improve Diagnosis and Treatment of Asthma
11.1.8 The Importance of Adherence and Early Diagnosis
11.1.9 Developments in Alpha-1 Antitrypsin Deficiency
11.1.10 Other Trends and Developments in Asthma and COPD
11.2 Interview with a Company Developing Pipeline Drugs for Asthma and COPD
11.2.1 Asthma and COPD Treatments in 2014-2024
11.2.2 Personalised Therapies for Asthma and COPD?
11.2.3 Drivers and Restraints in the Market
11.2.4 The Outlook for the Asthma and COPD Market
11.3 Interview with Monica Fletcher, Chief Executive of Education for Health and Chair of the European Lung Foundation (ELF), Sheffield, UK
11.3.1 The Importance of Education
11.3.2 Educating Healthcare Professionals and Patients
11.3.3 Missing the Diagnosis of COPD in Some Patient Populations
11.3.4 Global and Gender Issues in COPD
11.3.5 Improving Shared Understanding and Correct Inhaler Technique
11.3.6 The Growing Importance of Online Education
11.3.7 Engaging Patients Using Telehealth?
11.3.8 The Changing Impact of Education on Asthma and COPD
11.4 Interview with Daphne Tsitoura, Senior Medical Director, Clinical Drug Development/Discovery Medicine, GlaxoSmithKline, UK
11.4.1 Unmet Needs in Asthma
11.4.2 The Asthma Market: Reaching Saturation?
11.4.3 Phenotypically-Tailored Therapies?
11.4.4 Difficulties with COPD Diagnosis
11.4.5 Importance of Inhalers in the Asthma and COPD Market
11.4.6 Research Emphasis on COPD?
11.4.7 Combinations for COPD
11.4.8 Views on Telehealth
11.4.9 Views on Personalised Medicine
11.4.10 On Novel Targets
11.4.11 The Ten-Year Outlook for the Asthma and COPD Market
11.5 Interview with Barbara Yawn, Director of Research at Olmsted Medical Center and Adjunct Professor, Department of Family and Community Health, University of Minnesota, USA
11.5.1 Unmet Needs in Asthma
11.5.2 The Impact of Inhalers in Asthma and COPD
11.5.3 The Impact of New Drug Classes for COPD
11.5.4 Towards Personalised Medicine in Asthma and COPD
11.5.5 Views on Leukotriene Inhibitors
11.5.6 Anti-Inflammatory Drugs: More Research Required
11.5.7 LABA Monotherapy Drugs: Fading Away?
11.5.8 LABA/LAMA Combination Drugs in COPD
11.5.9 Views On Telehealth
11.5.10 Under-Diagnosis in COPD
11.5.11 The Ten-Year Outlook for the Asthma and COPD Market
11.6 Interview with Ahmed Wagih, Product Manager, Respiratory Franchise (Seretide, Flixotide and Ventolin) at GSK, UK
11.6.1 Rising Prevalence of COPD in the Middle East
11.6.2 Towards Personalised Medicine
11.6.3 Changes to Treatment Guidelines for Asthma and COPD
11.6.4 Key Areas of Focus in Asthma and COPD
11.6.5 Views on Generic Competition
11.6.6 Improving COPD Diagnostics
11.6.7 Views on LAMA/LABA Combinations
11.6.8 Views on Telehealth
12. Conclusions
12.1 Asthma and COPD Therapies: A Maturing Market
12.2 The World Asthma and COPD Therapies Market in 2013
12.2.1 Current Leading Asthma and COPD Therapies Segments
12.2.2 Leading Asthma and COPD Therapies
12.2.3 Leading Asthma and COPD Therapies Companies
12.2.4 Leading Regional and National Markets
12.3 World Asthma and COPD Therapies Market Forecast 2014-2024
12.4 Asthma and COPD Therapies Late-Stage Pipeline
12.5 The Future of the Asthma and COPD Therapies Market?
12.5.1 Growth in Anti-Inflammatory and Combination Drugs
12.5.2 Towards Personalised Medicine
12.5.3 Unmet Needs in Asthma and COPD
12.5.4 Strategies for Growth in 2014-2024


List of Tables
Table 1.1 Asthma and COPD Therapies: Leading National Markets Forecast 2014 ($m, AGR%)
Table 2.1 Classification of Respiratory Diseases, 2014
Table 2.2 Causes of Asthma, 2014
Table 2.3 Triggers of Asthma, 2014
Table 2.4 Clinical Trial Phases
Table 2.5 Currency Exchange Rates, 2013
Table 3.1 World Respiratory Drugs Market: Revenues ($m) and Market Shares (%) by Therapeutic Area, 2013
Table 3.2 Top 10 Asthma and COPD Therapies: Revenue ($m), 2013
Table 3.3 World Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 3.4 World Asthma Therapies Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 3.5 World COPD Therapies Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 3.6 World Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 3.7 Market Shares (%) of Leading Asthma and COPD Therapies Market Segments, 2013, 2018 and 2024
Table 4.1 World Asthma and COPD Therapies Market: Revenues ($m) and Market Shares (%) by Region, 2013
Table 4.2 World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Region, 2013-2024
Table 4.3 Market Shares (%) of Leading Regional Asthma and COPD Therapies Markets, 2013, 2018 and 2024
Table 4.4 World Asthma and COPD Therapies Market: Revenues ($m) and Market Shares (%) by National Market, 2013
Table 4.5 World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%) by National Market, 2013-2024
Table 4.6 Market Shares (%) of Leading National Asthma and COPD Therapies Markets, 2013, 2018 and 2024
Table 4.7 US Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.8 Japanese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.9 EU5 Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%) by National Market, 2013-2024
Table 4.10 German Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.11 French Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.12 UK Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.13 Italian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.14 Spanish Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.15 BRIC Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%) by National Market, 2013-2024
Table 4.16 Chinese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.17 Brazilian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.18 Indian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.19 Russian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 4.20 Mexican Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
Table 5.1 Bronchodilator Monotherapy Market: Revenues ($m) and Market Shares (%) by Drug Class, 2013
Table 5.2 Leading Bronchodilators: Revenues ($m) and Market Shares (%), 2013
Table 5.3 Bronchodilator Monotherapy Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug Class, 2013-2024
Table 5.4 Bronchodilator Monotherapy Market: Revenues ($m) and Market Shares (%) by Drug Class, 2018 and 2024
Table 5.5 Leading SABAs: Revenues ($m) and Market Shares (%), 2013
Table 5.6 SABAs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2013-2024
Table 5.7 SABAs Market: Market Shares (%) by Drug, 2013, 2018 and 2024
Table 5.8 GSK: Ventolin Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.9 Teva: ProAir Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.10 Merck: Proventil Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.11 Dainippon Sumitomo: Xopenex Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.12 Leading LABAs: Revenues ($m) and Market Shares (%), 2013
Table 5.13 LABAs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2013-2024
Table 5.14 LABAs Market: Market Shares (%) by Drug, 2013, 2018 and 2024
Table 5.15 Merck/Novartis: Foradil Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.16 GSK: Serevent Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.17 Novartis: Arcapta/Onbrez Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.18 Dainippon Sumitomo: Brovana Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.19 Boehringer Ingelheim: Striverdi Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.20 Leading Anticholinergics: Revenues ($m) and Market Shares (%), 2013
Table 5.21 Anticholinergics Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2013-2024
Table 5.22 Anticholinergics Market: Market Shares (%) by Drug, 2013, 2018 and 2024
Table 5.23 Boehringer Ingelheim: Spiriva Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.24 Boehringer Ingelheim: Atrovent Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 5.25 AstraZeneca/Forest/Menarini: Eklira/Tudorza/Bretaris Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.1 Anti-Inflammatory Drugs Market: Revenues ($m) and Market Shares (%) by Drug Class, 2013
Table 6.2 Leading Anti-Inflammatory Drugs: Revenues ($m) and Market Shares (%), 2013
Table 6.3 Anti-Inflammatory Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug Class, 2013-2024
Table 6.4 Anti-Inflammatory Drugs Market: Revenues ($m) and Market Shares (%) by Drug Class, 2018 and 2024
Table 6.5 Leading Corticosteroids: Revenues ($m) and Market Shares (%), 2013
Table 6.6 Corticosteroids Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2013-2024
Table 6.7 Corticosteroids Market: Market Shares (%) by Drug, 2013, 2018 and 2024
Table 6.8 GSK: Flixotide/Flovent Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.9 AstraZeneca: Pulmicort Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.10 Teva: QVAR Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.11 Merck: Asmanex Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.12 Leading Anti-Leukotrienes: Revenues ($m) and Market Shares (%), 2013
Table 6.13 Anti-Leukotrienes Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2013-2024
Table 6.14 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2013, 2018 and 2024
Table 6.15 Merck: Singulair Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.16 Monoclonal Antibodies Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2013-2024
Table 6.17 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2013, 2018 and 2024
Table 6.18 Novartis/Roche: Xolair Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.19 Teva: Cinquil Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.20 GSK: Mepolizumab Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.21 AstraZeneca/Kyowa Hakko Kirin: Benralizumab Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.22 Roche: Lebrikizumab Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.23 Regeneron/Sanofi: Dupilumab Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.1 Leading Combination Drugs: Revenues ($m) and Market Shares (%), 2013
Table 7.2 Combination Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2013-2024
Table 7.3 Combination Drugs Market: Market Shares (%) by Drug, 2013, 2018 and 2024
Table 7.4 GSK: Advair/Seretide Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.5 AstraZeneca: Symbicort Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.6 Boehringer Ingelheim: Combivent Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.7 Merck: Dulera Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 8.1 Leading Asthma and COPD Drug Manufacturers: Asthma and COPD Drugs Revenue ($m), Market Share (%), 2013
Table 8.2 Leading Asthma and COPD Drug Manufacturers: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 8.3 Leading Asthma and COPD Drug Manufacturers: Revenues ($m) and Market Shares (%), 2018 and 2024
Table 8.4 AstraZeneca: Overview, 2014
Table 8.5 AstraZeneca: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2013
Table 8.6 AstraZeneca: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2013-2024
Table 8.7 AstraZeneca: Asthma and COPD Therapies Pipeline, 2014
Table 8.8 Boehringer Ingelheim: Overview, 2014
Table 8.9 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2013
Table 8.10 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2013-2024
Table 8.11 GSK: Overview, 2014
Table 8.12 GSK: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2013
Table 8.13 GSK: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2013-2024
Table 8.14 GSK: Asthma and COPD Therapies Pipeline, 2014
Table 8.15 Merck: Overview, 2014
Table 8.16 Merck: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2013
Table 8.17 Merck: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2013-2024
Table 8.18 Novartis: Overview, 2014
Table 8.19 Novartis: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2013
Table 8.20 Novartis: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2013-2024
Table 8.21 Novartis: Asthma and COPD Therapies Pipeline, 2014
Table 8.22 Roche: Overview, 2014
Table 8.23 Roche: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2013-2024
Table 8.24 Teva: Overview, 2014
Table 8.25 Teva: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2013
Table 8.26 Teva: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2013-2024
Table 8.27 Teva: Asthma and COPD Therapies Pipeline, 2014
Table 9.1 Asthma and COPD Drugs Pipeline by Segment, 2014
Table 9.2 Bronchodilators Pipeline: Phase 3 Drugs, 2014
Table 9.3 Bronchodilators Pipeline: Phase 2 Drugs, 2014
Table 9.4 Bronchodilators Pipeline: Phase 1 and Preclinical Drugs, 2014
Table 9.5 Anti-Inflammatory Drugs Pipeline: Phase 3 Drugs, 2014
Table 9.6 Anti-Inflammatory Drugs Pipeline: Phase 2 Drugs, 2014
Table 9.7 Anti-Inflammatory Drugs Pipeline: Phase 1 Drugs, 2014
Table 9.8 Anti-Inflammatory Drugs Pipeline: Preclinical Drugs, 2014
Table 9.9 Combination Drugs Pipeline: Phase 3 Drugs, 2014
Table 9.10 Combination Drugs Pipeline: Phase 2 Drugs, 2014
Table 9.11 Combination Drugs Pipeline: Phase 1 and Preclinical Drugs, 2014
Table 9.12 Other Asthma and COPD Drugs Pipeline, 2014
Table 12.1 Asthma and COPD Drugs Late-Stage Pipeline, 2014

List of Figures
Figure 1.1 Leading Companies: Asthma and COPD Revenues as % of Net Revenue, 2013
Figure 1.2 Global Asthma and COPD Therapies Market Segmentation Overview, 2014
Figure 2.1 Summary of GINA Guidance for Asthma Treatment, 2014
Figure 2.2 Summary of GOLD Guidance for COPD Treatment, 2014
Figure 3.1 World Respiratory Drugs Market: Revenues ($m) by Therapeutic Area, 2013
Figure 3.2 World Respiratory Drugs Market: Market Shares (%) by Therapeutic Area, 2013
Figure 3.3 Top 10 Asthma and COPD Therapies: Market Share (%), 2013
Figure 3.4 World Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 3.5 World Asthma Therapies Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 3.6 World COPD Therapies Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 3.7 World Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%) by Drug Class, 2013-2024
Figure 3.8 World Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2013
Figure 3.9 World Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2018
Figure 3.10 World Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2024
Figure 3.11 World Asthma and COPD Therapies Market: Drivers and Restraints, 2014-2024
Figure 4.1 World Asthma and COPD Therapies Market: Revenues ($m) by Region, 2013
Figure 4.2 World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2013
Figure 4.3 World Asthma and COPD Therapies Market Forecast: Revenues ($m) by Region, 2013-2024
Figure 4.4 World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2018
Figure 4.5 World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2024
Figure 4.6 World Asthma and COPD Therapies Market: Revenues ($m) by National Market, 2013
Figure 4.7 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2013
Figure 4.8 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2018
Figure 4.9 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2024
Figure 4.10 US Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 4.11 Japanese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 4.12 EU5 Asthma and COPD Therapies Market Forecast: Revenues ($m) by National Market, 2013-2024
Figure 4.13 German Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 4.14 French Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 4.15 UK Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 4.16 Italian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 4.17 Spanish Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 4.18 BRIC Asthma and COPD Therapies Market Forecast: Revenues ($m) by National Market, 2013-2024
Figure 4.19 Chinese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 4.20 Brazilian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 4.21 Indian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 4.22 Russian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 4.23 Mexican Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), 2013-2024
Figure 5.1 Bronchodilator Monotherapy Market: Revenues ($m) by Drug Class, 2013
Figure 5.2 Bronchodilator Monotherapy Market: Market Shares (%) by Drug Class, 2013
Figure 5.3 Bronchodilator Monotherapy Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 5.4 Bronchodilator Monotherapy Market: Revenues ($m) by Drug Class, 2018
Figure 5.5 Bronchodilator Monotherapy Market: Market Shares (%) by Drug Class, 2018
Figure 5.6 Bronchodilator Monotherapy Market: Revenues ($m) by Drug Class, 2024
Figure 5.7 Bronchodilator Monotherapy Market: Market Shares (%) by Drug Class, 2024
Figure 5.8 SABAs Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 5.9 SABAs Market: Market Shares (%) by Drug, 2013
Figure 5.10 SABAs Market: Market Shares (%) by Drug, 2018
Figure 5.11 SABAs Market: Market Shares (%) by Drug, 2024
Figure 5.12 GSK: Ventolin Revenue ($m), AGR (%), 2013-2024
Figure 5.13 Teva: ProAir Revenue ($m), AGR (%), 2013-2024
Figure 5.14 Merck: Proventil Revenue ($m), AGR (%), 2013-2024
Figure 5.15 Dainippon Sumitomo: Xopenex Revenue ($m), AGR (%), 2013-2024
Figure 5.16 LABAs Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 5.17 LABAs Market: Market Shares (%) by Drug, 2013
Figure 5.18 LABAs Market: Market Shares (%) by Drug, 2018
Figure 5.19 LABAs Market: Market Shares (%) by Drug, 2024
Figure 5.20 Merck/Novartis: Foradil Revenue ($m), AGR (%), 2013-2024
Figure 5.21 GSK: Serevent Revenue ($m), AGR (%), 2013-2024
Figure 5.22 Novartis: Arcapta/Onbrez Revenue ($m), AGR (%), 2013-2024
Figure 5.23 Dainippon Sumitomo: Brovana Revenue ($m), AGR (%), 2013-2024
Figure 5.24 Boehringer Ingelheim: Striverdi Revenue ($m), AGR (%), 2013-2024
Figure 5.25 Anticholinergics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 5.26 Anticholinergics Market: Market Shares (%) by Drug, 2013
Figure 5.27 Anticholinergics Market: Market Shares (%) by Drug, 2018
Figure 5.28 Anticholinergics Market: Market Shares (%) by Drug, 2024
Figure 5.29 Boehringer Ingelheim: Spiriva Revenue ($m), AGR (%), 2013-2024
Figure 5.30 Boehringer Ingelheim: Atrovent Revenue ($m), AGR (%), 2013-2024
Figure 5.31 AstraZeneca/Forest/Menarini: Eklira/Tudorza/Bretaris Revenue ($m), AGR (%), 2013-2024
Figure 6.1 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2013
Figure 6.2 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2013
Figure 6.3 Anti-Inflammatory Drugs Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.4 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2018
Figure 6.5 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2018
Figure 6.6 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2024
Figure 6.7 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2024
Figure 6.8 Corticosteroids Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.9 Corticosteroids Market: Market Shares (%) by Drug, 2013
Figure 6.10 Corticosteroids Market: Market Shares (%) by Drug, 2018
Figure 6.11 Corticosteroids Market: Market Shares (%) by Drug, 2024
Figure 6.12 GSK: Flixotide/Flovent Revenue ($m), AGR (%), 2013-2024
Figure 6.13 AstraZeneca: Pulmicort Revenue ($m), AGR (%), 2013-2024
Figure 6.14 Teva: QVAR Revenue ($m), AGR (%), 2013-2024
Figure 6.15 Merck: Asmanex Revenue ($m), AGR (%), 2013-2024
Figure 6.16 Anti-Leukotrienes Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.17 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2013
Figure 6.18 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2018
Figure 6.19 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2024
Figure 6.20 Merck: Singulair Revenue ($m), AGR (%), 2013-2024
Figure 6.21 Monoclonal Antibodies Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.22 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2018
Figure 6.23 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2024
Figure 6.24 Novartis/Roche: Xolair Revenue ($m), AGR (%), 2013-2024
Figure 6.25 Teva: Cinquil Revenue ($m), AGR (%), 2013-2024
Figure 6.26 GSK: Mepolizumab Revenue ($m), AGR (%), 2013-2024
Figure 6.27 AstraZeneca/Kyowa Hakko Kirin: Benralizumab Revenue ($m), AGR (%), 2013-2024
Figure 6.28 Roche: Lebrikizumab Revenue ($m), AGR (%), 2013-2024
Figure 6.29 Regeneron/Sanofi: Dupilumab Revenue ($m), AGR (%), 2013-2024
Figure 7.1 Combination Drugs Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 7.2 Combination Drugs Market: Market Shares (%) by Drug, 2013
Figure 7.3 Combination Drugs Market: Market Shares (%) by Drug, 2018
Figure 7.4 Combination Drugs Market: Market Shares (%) by Drug, 2024
Figure 7.5 GSK: Advair/Seretide Revenue ($m), AGR (%), 2013-2024
Figure 7.6 AstraZeneca: Symbicort Revenue ($m), AGR (%), 2013-2024
Figure 7.7 Boehringer Ingelheim: Combivent Revenue ($m), AGR (%), 2013-2024
Figure 7.8 Merck: Dulera Revenue ($m), AGR (%), 2013-2024
Figure 8.1 Leading Asthma and COPD Drug Manufacturers: Revenue ($m), 2013
Figure 8.2 Leading Asthma and COPD Drug Manufacturers: Market Share (%), 2013
Figure 8.3 Leading Asthma and COPD Drug Manufacturers: Revenues ($m), 2018
Figure 8.4 Leading Asthma and COPD Drug Manufacturers: Market Shares (%), 2018
Figure 8.5 Leading Asthma and COPD Drug Manufacturers: Revenues ($m), 2024
Figure 8.6 Leading Asthma and COPD Drug Manufacturers: Market Shares (%), 2024
Figure 8.7 AstraZeneca: Asthma and COPD Therapies Revenue ($m) by Drug, 2013
Figure 8.8 AstraZeneca: Asthma and COPD Therapies Revenue Share (%) by Drug, 2013
Figure 8.9 AstraZeneca: Asthma and COPD Therapies Revenue ($m), AGR (%), 2013-2024
Figure 8.10 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m) by Drug, 2013
Figure 8.11 Boehringer Ingelheim: Asthma and COPD Therapies Revenue Share (%) by Drug, 2013
Figure 8.12 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m), AGR (%), 2013-2024
Figure 8.13 GSK: Asthma and COPD Therapies Revenue ($m) by Drug, 2013
Figure 8.14 GSK: Asthma and COPD Therapies Revenue Share (%) by Drug, 2013
Figure 8.15 GSK: Asthma and COPD Therapies Revenue ($m), AGR (%), 2013-2024
Figure 8.16 Merck: Asthma and COPD Therapies Revenue ($m) by Drug, 2013
Figure 8.17 Merck: Asthma and COPD Therapies Revenue Share (%) by Drug, 2013
Figure 8.18 Merck: Asthma and COPD Therapies Revenue ($m), AGR (%), 2013-2024
Figure 8.19 Novartis: Asthma and COPD Therapies Revenue ($m) by Drug, 2013
Figure 8.20 Novartis: Asthma and COPD Therapies Revenue Share (%) by Drug, 2013
Figure 8.21 Novartis: Asthma and COPD Therapies Revenue ($m), AGR (%), 2013-2024
Figure 8.22 Roche: Asthma and COPD Therapies Revenue ($m), AGR (%), 2013-2024
Figure 8.23 Teva: Asthma and COPD Therapies Revenue ($m) by Drug, 2013
Figure 8.24 Teva: Asthma and COPD Therapies Revenue Share (%) by Drug, 2013
Figure 8.25 Teva: Asthma and COPD Therapies Revenue ($m), AGR (%), 2013-2024
Figure 9.1 Asthma and COPD Drugs Pipeline by Segment, 2014
Figure 10.1 Asthma and COPD Therapies Market: Strengths and Weaknesses, 2014-2024
Figure 10.2 Asthma and COPD Therapies Market: Opportunities and Threats, 2014-2024
Figure 10.3 Porter’s Five Forces Analysis of the Asthma and COPD Therapies Market, 2014-2024
Figure 12.1 World Asthma and COPD Therapies Market Forecast: Revenues ($m) by Therapeutic Area, 2013-2024


【レポートのキーワード】

喘息、COPD(慢性閉塞性肺疾患)、治療薬、製薬

★調査レポート[世界の喘息及びCOPD(慢性閉塞性肺疾患)治療薬市場] ( Asthma and COPD Therapies Market Forecast 2014-2024 : Opportunities for Leading Companies / VGAIN4120203) 販売に関する免責事項
[世界の喘息及びCOPD(慢性閉塞性肺疾患)治療薬市場] ( Asthma and COPD Therapies Market Forecast 2014-2024 : Opportunities for Leading Companies / VGAIN4120203) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆